Home>Topics>Companies>Baxter International

Baxter International BAX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Health Care: Some Healthy Bargains Still Remain

      Headlines

      Wed, 1 Oct 2014

      Narrow Medium $39.90 Baxter $84.00 Wide Low $67 ..... stock look undervalued. Baxter BAX While competition is increasing for Advate, Baxter 's highly profitable hemophilia ..... Intangible assets--like Baxter 's strong brands, patent

    2. Baxter plans to open R&D center in Mass. for Baxalta spinoff

      Headlines

      Mon, 29 Sep 2014

      Sept 29 (Reuters) - Baxter International Inc on Monday said it would form a research and development center in Cambridge, Massachusetts, for the biopharmaceutical business it expects to spin off as a separate company in mid-2015.

    3. BioMed Realty inks 200K square foot, 12-year lease with Baxter Healthcare

      Headlines

      Mon, 29 Sep 2014

      foot building at 650 East Kendall Street in Cambridge, MA is owned through a JV with Prudential Real Estate Investors. Baxter will be establishing a new global innovation and R&D center at the site for its biopharmaceuticals business. BioMed

    4. Kamada extends Glassia supply agreement

      Headlines

      Mon, 29 Sep 2014

      AAT) treatment, Glassia , to Baxter International 's ( BAX -0.6% ) biopharmaceutical ..... payments for Glassia produced by Baxter is not expected to begin before 2018. Baxter is the exclusive distributor of

    5. Kamada extends emphysema drug deal with Baxter through 2017

      Headlines

      Mon, 29 Sep 2014

      JERUSALEM, Sept 29 (Reuters) - Israeli drugmaker Kamada said on Monday it extended an agreement with Baxter International to supply a drug to treat emphysema through 2017.

    6. Baxter reports on October 16 before the open

      Headlines

      Thu, 25 Sep 2014

      Baxter International ( BAX -1.2% ) reports Q3 results on October 16. Its conference call will commence at 7:30 am CT. Consensus view is EPS of $1.30 on revenues of $4.2B. Post your comment!

    7. Update: Merrimack Licenses MM-398 - Value Potential Dramatically Improves

      Headlines

      Wed, 24 Sep 2014

      company announced today a license agreement with Baxter (NYSE: BAX ) for MM-398, sending shares as much as 27 ..... Some key highlights of the license agreement with Baxter are as follows: Baxter agrees to develop and market MM-398 Complete

    8. Merrimack up premarket

      Headlines

      Wed, 24 Sep 2014

      Merrimack Pharmaceuticals (NASDAQ: MACK ) is up 20% premarket on robust volume in response to its collaboration with Baxter . Post your comment!

    9. US STOCKS-Bed, Bath & Beyond, Merrimack Pharma surge in premarket

      Headlines

      Wed, 24 Sep 2014

      NEW YORK, Sept 24 (Reuters) - Merrimack Pharmaceuticals shares were surging in premarket trade, up 24.5 percent to $8.95 after the company said it reached a deal to develop and market Merrimack's pancreatic cancer drug outside the U.S. with Baxter International .

    10. Baxter to market Merrimack's cancer drug outside U.S.

      Headlines

      Wed, 24 Sep 2014

      Sept 24 (Reuters) - Drug developer Merrimack Pharmaceuticals Inc said it would partner with Baxter International Inc to develop and market its pancreatic cancer drug outside the United States, sending its shares up as much as 27 percent premarket.

    « Prev12345Next »
    Content Partners